Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

AtriCure (ATRC) Shares Outstanding (Diluted Average) (2019 - 2025)

AtriCure (ATRC) has disclosed Shares Outstanding (Diluted Average) for 7 consecutive years, with $47.8 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 1.67% to $47.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $47.8 million through Dec 2025, up 1.67% year-over-year, with the annual reading at $47.8 million for FY2025, 1.67% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $47.8 million at AtriCure, roughly flat from $47.7 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $47.8 million in Q4 2025, with the low at $44.6 million in Q1 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $46.4 million, with a median of $46.3 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Diluted Average) grew 9.29% in 2021, then decreased 0.91% in 2022.
  • Over 5 years, Shares Outstanding (Diluted Average) stood at $46.0 million in 2021, then decreased by 0.65% to $45.7 million in 2022, then increased by 1.24% to $46.3 million in 2023, then grew by 1.42% to $47.0 million in 2024, then increased by 1.67% to $47.8 million in 2025.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $47.8 million, $47.7 million, and $47.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.